共 68 条
[1]
Forouzanfar MH(2016)Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 Lancet 388 1659-1724
[2]
Liu P(2017)Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015 JAMA 317 165-182
[3]
Roth GA(2018)Dissecting hypertension in Russia: identifying aetiological and behavioural factors associated with treatment and control Eur J Pub Health 2 199-204
[4]
Leon DA(2013)Economic burden of cardiovascular diseases in the Russian Federation Value Health Reg Issues 21 D101-D103
[5]
Malyutina S(2019)May measurement month 2017 in Russia: hypertension treatment and control, Europe Eur Heart J Suppl 19 2602-788
[6]
Kudryavtsev AV(2020)Contribution of the ESSE-RF study to preventive healthcare in Russia Cardiovasc Therapy Prevent 362 782-1098
[7]
Kontsevaya A(2003)Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 170 1092-400
[8]
Kalinina A(2015)Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: a EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis Am Heart J 31 391-811
[9]
Oganov R(2017)The treatment effect of an ACE-inhibitor based regimen with perindopril in relation to beta-blocker use in 29,463 patients with vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS trials Cardiovasc Drugs Ther 30 805-66
[10]
Rotar O(2014)AchievemenT of target resting HEart rate on beta-blockers in patients with stable angiNA and hypertension (ATHENA) in routine clinical practice in Russia Curr Med Res Opin 1 59-842